Low Testosterone and Cancer Risk in 2026: What a Study of 26,000 Men Means Before You Write Off That Blood Test

The Androgens In Men Study is one of the largest hormone studies ever conducted in men. Led by Professor Bu Yeap at the University of Western Australia, the research team pooled individual data from more than 26,000 men across 11 long-running cohort studies in Australia, the United States, and Europe. Blood samples taken earlier in the men's lives were analyzed for testosterone, dihydrotestosterone (DHT), sex hormone-binding globulin (SHBG), and luteinizing hormone (LH), then matched against cancer diagnoses and deaths that occurred years down the line.

The headline result: men in the lowest one-fifth of testosterone levels were 18% more likely to die from cancer than men in the highest one-fifth, even after the researchers adjusted for age and other health-related factors. Very low testosterone was linked to a higher risk of both fatal and non-fatal cancers, according to ScienceDaily's report on the findings.

The association wasn't a smooth slope across all testosterone levels. Cancer death risk began climbing when baseline testosterone fell below 8.6 nmol/L — roughly 250 ng/dL in the units most US labs report. For context, healthy younger men typically run between 10 and 30 nmol/L (about 290 to 865 ng/dL), and levels drift downward with age.

That threshold matters because it sits close to where many clinical guidelines already draw the line for diagnosing testosterone deficiency. In other words, the men at elevated risk in this study weren't just at the low end of normal — they were in territory where most doctors would already be asking follow-up questions.

This is the part worth reading twice: the study shows an association, not causation. Nothing in the data proves that low testosterone causes cancer, and Professor Yeap's team is explicit that there's no evidence that giving men testosterone would lower their cancer risk. "We haven't got any evidence yet that actually giving men testosterone will reduce that risk," Yeap noted in the university's announcement.

So why would low testosterone track with cancer deaths at all? Testosterone levels are influenced by factors that independently affect cancer risk — body weight, physical activity, and conditions like type 2 diabetes among them. Chronically low levels can reflect underlying metabolic illness that hasn't been diagnosed yet. That's exactly why the researchers frame low testosterone as a biomarker: a measurable signal that a man's overall health deserves a closer look, including weight, blood sugar, blood pressure, and age-appropriate cancer screening.

The practical takeaway isn't "low T will give you cancer." It's that a genuinely low reading is a reason to get a full checkup — not something to shrug off or self-treat with over-the-counter boosters.

For decades, men and many doctors have assumed testosterone and prostate cancer were tightly linked — a legacy of older research suggesting testosterone "feeds" prostate tumors. AIMS found something different: testosterone levels showed no relationship with prostate cancer risk. "There's no evidence they are related," Yeap said of the two.

Instead, the study found that low SHBG and low luteinizing hormone — two other hormones measured in the same blood panels — were associated with higher prostate cancer risk. That's a finding researchers will keep untangling, but for patients it reinforces a theme that has been building in recent years, including in the FDA's recent testosterone label changes: the old assumption that normal testosterone levels endanger the prostate is not holding up in modern data. Screening still matters — men on testosterone therapy are typically monitored with PSA testing — but testosterone itself is looking less like the villain it was once thought to be.

If you've been weighing testosterone replacement therapy, this study changes the conversation in two ways — one encouraging, one cautionary.

The encouraging part: it adds to the case that knowing your number matters. Symptoms like fatigue, low sex drive, erectile difficulties, and loss of muscle mass are worth investigating, and a morning blood test is the only way to know whether low testosterone is part of the picture. Current guidelines call for two separate morning total testosterone measurements before a diagnosis is made — something recent research shows only about 1 in 5 men starting TRT actually received.

The cautionary part: this study is not a reason to start TRT to prevent cancer. No trial has shown testosterone therapy reduces cancer risk, and treatment has real considerations — it can suppress sperm production and fertility, raise red blood cell counts, and cause acne or fluid retention, and it requires screening and ongoing lab monitoring. Men with a history of prostate or breast cancer, untreated severe sleep apnea, or plans to have children soon need a careful conversation before starting. That decision belongs with a licensed provider who has your labs, your history, and your goals in front of them.

If the symptoms of low testosterone sound familiar — or this research has you wanting a baseline number — JoeyMed can help you take the first step from home. Our licensed providers can review your symptoms, order appropriate lab work, and walk you through what your results mean, including whether treatment makes sense or whether your levels point to other health issues worth addressing first. And because low testosterone often travels with related concerns like erectile dysfunction and weight, we can help you look at the whole picture, from ED treatment options to medical weight loss.

Visit joeymed.com/sexual-health to start a confidential online visit today. A single blood test won't tell you everything about your health — but as this study of 26,000 men shows, it can tell you where to start looking.